Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics (NQ: CYTK )

18.73 USD -1.12 (-5.64%)
Official Closing Price Updated: 4:52 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Cytokinetics

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
From GlobeNewswire News Releases
Cytokinetics Reports Fourth Quarter 2020 Financial Results
From GlobeNewswire News Releases
Cytokinetics Names Muna Bhanji to Board of Directors
Appointment Adds to Board Expertise in Commercial Development and Market Access as Company Prepares for Further Corporate Development 
From GlobeNewswire News Releases
Cytokinetics to Announce Fourth Quarter Results on February 25, 2021
From GlobeNewswire News Releases
Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants
Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach 
From GlobeNewswire News Releases
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM
Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals 
From GlobeNewswire News Releases
Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy
From GlobeNewswire News Releases
Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
From GlobeNewswire News Releases
Cytokinetics Regains European Rights to Omecamtiv Mecarbil
Company is Planning Regulatory Interactions in 2021 to Discuss Results of GALACTIC-HF and Expects to Evaluate Strategic Options for Co-Commercialization and Licensing 
From GlobeNewswire News Releases
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
Additional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS 
From GlobeNewswire News Releases
Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2
Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left... 
From GlobeNewswire News Releases
Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the 17th Global Cardiovascular Clinical Trialists
From GlobeNewswire News Releases
Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND
From GlobeNewswire News Releases
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From GlobeNewswire News Releases
Cytokinetics Announces Additional Results From GALACTIC-HF to be Presented at the 17th Global Cardiovascular Clinical Trialists Forum
Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank Meeting 
From GlobeNewswire News Releases
Cytokinetics to Participate in Upcoming Investor Conferences
From GlobeNewswire News Releases
Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen
From GlobeNewswire News Releases
Cytokinetics Names Nancy Wysenski to Board of Directors
Appointment Strengthens Commercial, Market Access and Specialty Sales Expertise as Company Advances Pipeline Toward Potential Commercialization 
From GlobeNewswire News Releases
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
From GlobeNewswire News Releases
Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020
New Findings from Studies of Cardiac Myosin Inhibitors in Animal Models of Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction 
From GlobeNewswire News Releases
Cytokinetics Announces Results From GALACTIC-HF Presented at Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions and Published in the New England Journal of Medi
From GlobeNewswire News Releases
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
From GlobeNewswire News Releases
Cytokinetics Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Cytokinetics to Announce Third Quarter Results on November 4, 2020
From GlobeNewswire News Releases
Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure
From GlobeNewswire News Releases
Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events 
From PR Newswire
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.